TAM
AQST icon

Tiverton Asset Management’s Aquestive Therapeutics AQST Stock Holding History

Tiverton Asset Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-10,742
Closed -$45K – 711
2019
Q2 		$45K Hold
10,742
– – ﹤0.01% 669
2019
Q1 		$74K Buy
+10,742
New +$75.3K ﹤0.01% 608

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Tiverton Asset Management's AQST Position: Q3 2019 in Review

Tiverton Asset Management sold out of Aquestive Therapeutics (AQST) in Q3 2019, closing a stake of 10,742 shares — an estimated $45K sold.

Tiverton Asset Management first reported a position in AQST in Q1 2019 and held it in 2 quarters. The position peaked at $74K in Q1 2019. 35 funds tracked by Wall St. Rank hold AQST as of Q3 2019.

  • Tiverton Asset Management reported no remaining Aquestive Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Tiverton Asset Management sold 10,742 Aquestive Therapeutics shares in Q3 2019, an estimated $45K.
  • Tiverton Asset Management first reported a position in Aquestive Therapeutics in Q1 2019 and held it in 2 quarters.
  • Tiverton Asset Management's Aquestive Therapeutics position peaked at $74K in Q1 2019.
  • 35 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.